Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Large Drop in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 1,517,000 shares, a decline of 10.2% from the November 15th total of 1,688,500 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 15,170.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of Swedish Orphan Biovitrum AB (publ) stock remained flat at $28.62 during trading hours on Friday. The firm’s 50-day simple moving average is $29.59 and its two-hundred day simple moving average is $28.08. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. Swedish Orphan Biovitrum AB has a 1 year low of $22.40 and a 1 year high of $32.25.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.